William Blair Issues Pessimistic Estimate for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at William Blair dropped their FY2025 earnings per share estimates for Neurocrine Biosciences in a research note issued to investors on Monday, July 14th. William Blair analyst M. Minter now anticipates that the company will earn $3.70 per share for the year, down from their previous forecast of $3.71. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share.

A number of other analysts have also weighed in on NBIX. HC Wainwright dropped their price objective on Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating for the company in a research note on Tuesday, April 22nd. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. Evercore ISI dropped their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Wall Street Zen lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. Finally, Guggenheim increased their price objective on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $131.24 on Tuesday. The firm has a market cap of $12.99 billion, a PE ratio of 44.49, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The business has a 50 day moving average price of $124.94 and a 200-day moving average price of $121.44.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). The company had revenue of $572.60 million for the quarter, compared to analysts’ expectations of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the company posted $1.20 EPS.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 457 shares of the stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the transaction, the insider owned 4,730 shares in the company, valued at approximately $638,550. This represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Charles Gorman sold 9,613 shares of the stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the completion of the transaction, the director owned 514,596 shares of the company’s stock, valued at approximately $61,947,066.48. This trade represents a 1.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,251 shares of company stock worth $14,978,602 in the last ninety days. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Neurocrine Biosciences by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock valued at $1,381,331,000 after acquiring an additional 122,681 shares in the last quarter. Dodge & Cox increased its holdings in shares of Neurocrine Biosciences by 83.5% during the first quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock valued at $612,129,000 after acquiring an additional 2,518,199 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Neurocrine Biosciences by 44.0% during the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after acquiring an additional 640,556 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 2.9% during the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company’s stock valued at $258,926,000 after acquiring an additional 53,610 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock valued at $255,523,000 after acquiring an additional 15,830 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.